Anästhesiologie
Publikationen 2011 (TOP)
Kuchenbauer F, Mah SM, Heuser M, McPherson A, Ruschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J, Döhner H, Döhner K, Marra MA, Camargo FD, Palmqvist L, Buske C, Humphries RK.
Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells.
Blood. 2011 Sep 22;118(12):3350-8.
Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, KindlerT, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K:
Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia: A study of the German-Austrian AML Study Group (AMLSG).
J Clin Oncol. 2011 Jul 1;29(19):2709-16.
Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Kündgen A, Schmidt-Wolf IGH, Götze K, Nachbaur D, Pfreundschuh M, Horst HA, Döhner H, Döhner K:
RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis on 945 Patients from the AML Study Group (AMLSG).
J Clin Oncol. 2011 Apr 1;29(10):1364-72.
Taskesen E, Bullinger L, Corbacioglu A, Sanders M, Erpelinck C, Wouters BJ, van der Poel-van de Luytgaarde S, Damm F, Krauter J, Ganser A, Schlenk RF, Lowenberg B, Delwel R, Dohner H, Valk PJ, Dohner K.
Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity.
Blood. 2011 Feb 24;117(8):2469-75.
Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF, for the German-Austrian AMLSG:
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2,853 adult patients with newly diagnosed AML.
Blood. 2011 Feb 17;117(7):2137-45.
Marcucci G, Haferlach T, Döhner H.
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications.
J Clin Oncol. 2011 Feb 10;29(5):475-86.
Mohr J, Helfrich H, Fuge M, Eldering E, Bühler A, Winkler D, Volden M, Kater A, Mertens D, te Raa D, Döhner H, Stilgenbauer S, Zenz T.
DNA damage induced transcriptional programme in CLL: biological and diagnostic implications of functional p53 testing.
Blood. 2011 Feb 3;117(5):1622-32.
Publikationen 2011 (Gesamtverzeichnis)
97.
Heuser M, Schlenk RF, Ganser A.
[Current treatment options in acute myeloid leukemia.]
Internist (Berl). 2011 Dec;52(12):1386-93. German.
96.
Grandchamp B, Hetet G, Kannengiesser C, Oudin C, Beaumont C, Rodrigues-Ferreira S, Amson R, Telerman A, Nielsen P, Kohne E, Balser C, Heimpel H.
A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene.
95.
Wahlers K, Menezes CN, Wong M, Mogoye B, Frean J, Romig T, Kern P, Grobusch MP.
Human cystic echinococcosis in South Africa.
Acta Trop. 2011 Dec;120(3):179-84.
94.
Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R; for the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group.
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
Blood. 2011 Dec 22;118(26):6760-6768.
93.
Russ AC, Sander S, Luck SC, Lang KM, Bauer M, Rücker FG, Kestler HA, Schlenk RF, Döhner H, Holzmann K, Döhner K, Bullinger L.
Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
Haematologica. 2011 Dec;96(12):1783-91.
92.
Farag SS, Maharry K, Zhang MJ, Pérez WS, George SL, Mrózek K, Dipersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ; Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cancer and Leukemia Group B (CALGB).
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Aged 60-70 Years with Acute Myeloid Leukemia in First Remission.
Biol Blood Marrow Transplant. 2011 Dec;17(12):1796-803.
91.
Schnaiter A, Mertens D, Stilgenbauer S.
Genetics of chronic lymphocytic leukemia.
Clin Lab Med. 2011 Dec;31(4):649-58.
90.
Giannopoulos K, Mertens D, Stilgenbauer S.
Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Expert Opin Pharmacother. 2011 Dec;12(18):2857-64.
89.
Rouhi A, Buske C.
Stem cells and beyond: report on the 40th Annual Scientific Meeting of the International Society of Experimental Hematology.
Expert Rev Hematol. 2011 Dec;4(6):591-2.
88.
Sanjmyatav J, Junker K, Matthes S, Muehr M, Sava D, Sternal M, Wessendorf S, Kreuz M, Gajda M, Wunderlich H, Schwaenen C.
Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma.
87.
Freudenmann M, Kurz S, von Baum H, Reick D, Schreff AM, Essig A, Lück C, Gonser T, Brockmann SO, Härter G, Eberhardt B, Embacher A, Höller C.
[Interdisciplinary management of a large Legionella outbreak in Germany].
86.
Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O, Karimi M, Bengtzen S, Nahi H, Uggla B, Tidefelt U, Höglund M, Paul C, Ekwall K, Döhner K, Lehmann S.
Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks.
Blood. 2011 Nov 17;118(20):5573-82.
85.
Noordermeer SM, Sanders MA, Gilissen C, Tonnissen E, van der Heijden A, Döhner K, Bullinger L, Jansen JH, Valk PJM, van der Reijden BA.
High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9 positive patients.
Blood. 2011 Nov 17;118(20):5613-21.
84.
Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L.
Clinical Efficacy of Immunochemotherapy with Fludarabine, Epirubicin and Rituximab (FER) in the Treatment of Chronic Lymphocytic Leukaemia and Prolymphocytic Leukaemia.
Eur J Haematol. 2011 Nov;87(5):426-33.
83.
Lück SC, Russ AC, Botzenhardt U, Paschka P, Schlenk RF, Döhner H, Fulda S, Döhner K, Bullinger L.
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups.
Leukemia. 2011 Nov;25(11):1728-38.
82.
Deshpande AJ, Rouhi A, Lin Y, Stadler C, Greif P, Arseni N, Opatz S, Quintanilla-Fend L, Holzmann K,
Hiddemann W, Döhner K, Döhner H, Xu G, Armstrong SA, Bohlander SK, Buske C.
The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice.
Leukemia. 2011 Nov;25(11):1718-27.
81.
Herold T, Jurinovic V, Metzeler KH, Boulesteix AL, Bergmann M, Seiler T, Mulaw M, Thoene S, Dufour A, Pasalic Z, Schmidberger M, Schmidt M, Schneider S, Kakadia PM, Feuring-Buske M, Braess J, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Bohlander SK.
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia.
80.
Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, Soden PE, Auger KR, Mirguet O, Doehner K, Delwel R, Burnett AK, Jeffrey P, Drewes G, Lee K, Huntly BJ, Kouzarides T.
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
79.
Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, Baum A, Lamche H, Küpcü Z, Jacobi A, Müller S, Hirt U, Adolf GR, Borges E.
A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high pro-apoptotic activity for treatment of B-cell malignancies.
Blood. 2011 Oct 13;118(15):4159-68.
78.
Mertens D, Bullinger L, Stilgenbauer S.
Chronic lymphocytic leukemia - genomics lead the way.
77.
Hütter ML, Schlenk RF.
Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.
Expert Opin Biol Ther. 2011 Oct;11(10):1369-80.
76.
Kamal I, Romig T, Kern P, Omer RA.
A molecular survey on cystic echinococcosis in Sinnar area, Blue Nile state (Sudan).
75.
Romig T, Omer RA, Zeyhle E, Hüttner M, Dinkel A, Siefert L, Elmahdi IE, Magambo J, Ocaido M, Menezes CN, Ahmed ME, Mbae C, Grobusch MP, Kern P.
Echinococcosis in sub-Saharan Africa: emerging complexity.
74.
Bartsch I, Sandrock K, Lanza F, Nurden P, Hainmann I, Pavlova A, Greinacher A, Tacke U, Barth M, Busse A, Oldenburg J, Bommer M, Strahm B, Superti-Furga A, Zieger B.
Deletion of human GP1BB and SEPT5 is associated with Bernard-Soulier syndrome, platelet secretion defect, polymicrogyria, and developmental delay.
Thromb Haemost. 2011 Sep;106(3):475-83.
73.
Gökbuget N, Basara N, Baurmann H, Beck J, Brüggemann M, Diedrich H, Güldenzoph B, Hartung G, Horst HA, Hüttmann A, Kobbe G, Naumann R, Ratei R, Reichle A, Serve H, Stelljes M, Viardot A, Wattad M, Hoelzer D.
High single drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Blood. 2011 Sep 29;118(13):3504-11.
72.
Kuchenbauer F, Mah SM, Heuser M, McPherson A, Ruschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J, Döhner H, Döhner K, Marra MA, Camargo FD, Palmqvist L, Buske C, Humphries RK.
Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells.
Blood. 2011 Sep 22;118(12):3350-8.
71.
Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, Scadden DT, Armstrong SA, Williams DA.
Differential niche and Wnt requirements during acute myeloid leukemia progression.
Blood. 2011 Sep 8;118(10):2849-56.
70.
Stilgenbauer S, Mertens D.
Toward chemotherapy-free treatment of CLL.
Blood. 2011 Sep 29;118(13):3451-2.
69.
Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer C, Böttcher S, Peter Staib, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst B, Hallek H, Wendtner CM.
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
J Clin Oncol. 2011 Sep 10;29(26):3559-66.
68.
Reiser M, Wieland A, Plachter B, Mertens T, Greiner J, Schirmbeck R.
The Immunodominant CD8 T Cell Response to the Human Cytomegalovirus Tegument Phosphoprotein pp65495-503 Epitope Critically Depends on CD4 T Cell Help in Vaccinated HLA-A*0201 Transgenic Mice.
J Immunology. 2011 Sep 1;187(5):2172-80.
67.
Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT.
AKT/FOXO Signaling Enforces Reversible Differentation Blockade in Myeloid Leukemias.
Cell. 2011 Sep 2;146(5):697-708.
66.
Sako Y, Tappe D, Fukuda K, Kobayashi Y, Itoh S, Frosch M, Grüner B, Kern P, Ito A.
Immunochromatographic test with recombinant Em18 antigen for the follow-up study of alveolar echinococcosis.
65.
Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, Canty AJ, Danska JS, Bohlander SK, Buske C, Minden MD, Golub TR, Jurisica I, Ebert BL, Dick JE.
Stem cell gene expression programs influence clinical outcome in human leukemia.
Nat Med. 2011 Aug 28;17(9):1086-93.
64.
Kayser S, Schlenk RF.
[Acute myeloid leukemia: from risk-adapted to genotype-specific therapy.]
Dtsch Med Wochenschr. 2011 Aug;136(31/32):1577-1580. German. No abstract available.
63.
Azimzadeh O, Scherthan H, Sarioglu H, Barjaktarovic Z, Conrad M, Vogt A, Calzada-Wack J, Neff F, Aubele M, Buske C, Atkinson MJ, Tapio S.
Rapid proteomic remodeling of cardiac tissue caused by total body ionizing radiation.
Proteomics. 2011 Aug;11(16):3299-311.
62.
Schönsteiner SS, Bommer M, Haenle MM, Klaus B, Scheuerle A, Schmid M, Mayer-Steinacker R.
Rare Phenomenon: Liver Metastases from Glioblastoma Multiforme.
J Clin Oncol. 2011 Aug 10;29(23):e668-71.
61.
Idler I, Bhattacharya N, Döhner H, Stilgenbauer S, Mertens D.
Immune modulatory agents in hematopoietic malignancies.
Cancer Treat Rev. 2011;37 Suppl 1:S2-7.
60.
Bhattacharya N, Diener S, Idler IS, Rauen J, Häbe S, Busch H, Habermann A, Zenz T, Döhner H, Stilgenbauer S, Mertens D.
Nurse-like cells show deregulated expression of genes involved in immunocompetence.
Br J Haematol. 2011 Aug;154(3):349-56.
59.
Heuser M, Yun H, Berg T, Yung E, Argiropoulos B, Kuchenbauer F, Park G, Hamwi I, Palmqvist L, Lai CK, Leung M, Lin G, Chaturvedi A, Thakur BK, Iwasaki M, Bilenky M, Thiessen N, Robertson G, Hirst M, Kent D, Wilson NK, Göttgens B, Eaves C, Cleary ML, Marra M, Ganser A, Humphries RK.
Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex.
58.
Nebe T, Bentzien F, Brügel M, Fiedler GM, Gutensohn K, Heimpel H, Krebs N, Ossendorf M, Schuff-Werner P, Stamminger G, Baum H.
Multizentrische Ermittlung von Referenzbereichen für Parameter des maschinellen Blutbildes
Laboratoriumsmedizin. 2011; 35, 3-38
57.
Heimpel H.
Vitamin B12-responsive pancytopenia mimicking myelodysplastic syndrome.
56.
Wittig-Blaich SM, Kacprzyk LA, Eismann T, Bewerunge-Hudler M, Kruse P, Winkler E, Strauss WS, Hibst R, Steiner R, Schrader M, Mertens D, Sültmann H, Wittig R.
Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.
55.
Stegelmann F, Bullinger L, Schlenk RF, Paschka P, Griesshammer M, Blersch C, Kuhn S, Schauer S, Döhner H, Döhner K.
DNMT3A mutations in myeloproliferative neoplasms.
Leukemia. 2011 Jul;25(7):1217-9.
54.
Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, Burkhardt B, Trautmann H, Gesk S, Andrusiewicz M, Berger H, Fey M, Harder L, Hasenclever D, Hummel M, Loeffler M, Mahn F, Martin-Guerrero I, Pellissery S, Pott C, Pfreundschuh M, Reiter A, Richter J, Rosolowski M, Schwaenen C, Stein H, Trümper L, Wessendorf S, Spang R, Küppers R, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe; German High-Grade Lymphoma Study Group; Berlin-Frankfurt-Münster-NHL trial group.
Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.
53.
Stelljes M, Corbacioglu A, Schlenk RF, Döhner K, Frühwald MC, Rossig C, Ehlert K, Silling G, Müller-Tidow C, Juergens H, Döhner H, Berdel WE, Kienast J, Koschmieder S.
Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein a from hematopoietic cells in a family with AML.
Leukemia. 2011 Jul;25(7):1209-10.
52.
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA.
MLL-rearranged Leukemia is Dependent on Aberrant H3K79 Methylation by DOT1L.
Cancer Cell. 2011 Jul 12;20(1):66-78.
51.
Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Döhner K, Peschel C, Oostendorp RA, Goetze KS.
Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first generation FLT3 tyrosine kinase inhibitors.
Cancer Res. 2011 Jul 1;71(13):4696-706.
50.
Herold T, Jurinovic V, Mulaw M, Seiler T, Dufour A, Schneider S, Kakadia PM, Feuring-Buske M, Braess J, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Bohlander SK.
Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20.
Genes Chromosomes Cancer. 2011 Jul;50(7):546-58.
49.
Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, KindlerT, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K.
Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia: A study of the German-Austrian AML Study Group (AMLSG).
J Clin Oncol. 2011 Jul 1;29(19):2709-16.
48.
Kern P, Grüner B, Wahlers K.
Diagnosis and course of echinococcocal diseases in the transplant setting.
47.
Schmitt M, Neubauer A, Greiner J, Xu X, Barth TF, Bechter K.
Spreading of Acute Myeloid Leukemia Cells by Trafficking along the Peripheral Outflow Pathway of Cerebrospinal Fluid.
Anticancer Res. 2011 Jun;31(6):2343-5.
46.
Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJ, Delwel R, Armstrong SA, Dohner H, Gilliland DG, Huntly BJ.
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.
Cancer Res. 2011 Jun 15;71(12):4117-4129.
45.
Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol. 2011 Jun 20;29(18):2493-8.
44.
Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA.
Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia.
Blood. 2011 Jun 16;117(24):6450-6458.
43.
Theilgaard-Mönch K, Boultwood J, Ferrari S, Giannopoulos K, Hernandez-Rivas JM, Kohlmann A, Morgan M, Porse B, Tagliafico E, Zwaan CM, Wainscoat J, Van den Heuvel-Eibrink M, Mills K*, Bullinger L*.
Gene expression profiling in MDS and AML: potential and future avenues.
Leukemia. 2011 Jun;25(6):909-20.
42.
Hofmann S, Greiner J.
Adoptive immunotherapy after allogeneic hematopoietic progenitor cell transplantation: New perspectives for transfusion medicine.
Transfus Med Hemother. 2011 Jun;38(3):173-182.
41.
Zhang L, Greiner J.
Leukemia-associated antigens are immunogenic and have prognostic value in acute myeloid leukemia.
Immunotherapy. 2011 Jun;3(6):697-9.
40.
Wacheck V, Lahn M, Dickinson G, Füreder W, Meyer R, Herndlhofer S, Füreder T, Dorfner G, Pillay S, André V, Burkholder TP, Akunda JK, Flye-Blakemore L, Van Bockstaele D, Schlenk RF, Sperr WR, Valent P.
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics.
Cancer Manag Res. 2011;3:157-75.
39.
Giehl K, Bachem M, Beil M, Böhm BO, Ellenrieder V, Fulda S, Gress TM, Holzmann K, Kestler HA, Kornmann M, Menke A, Möller P, Oswald F, Schmid RM, Schmidt V, Schirmbeck R, Seufferlein T, von Wichert G, Wagner M, Walther P, Wirth T, Adler G.
Inflammation, regeneration, and transformation in the pancreas: results of the Collaborative Research Center 518 (SFB 518) at the University of Ulm.
38.
Opel D, Naumann I, Schneider M, Bertele D, Debatin KM, Fulda S.
Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
37.
Schneider C, Pasqualucci L, Dalla-Favera R.
Molecular pathogenesis of diffuse large B-cell lymphoma.
36.
Härter G.
[Suspicion of HIV-infection: which symptoms should be warning lights?].
35.
Kletting P, Kull T, Bunjes D, Luster M, Reske SN, Glatting G.
Optimal preloading in radioimmunotherapy with anti-cD45 antibody.
Med Phys. 2011 May;38(5):2572-8.
34.
Zizer E, Bommer M, Barth T, Dikopoulos N.
Severe Agranulocytosis as a Rare Side Effect of Pegylated Interferon Therapy for Chronic Hepatitis B.
Z Gastroenterol. 2011 May;49(5):596-598.
33.
Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, Ehninger G, Steckel NK, Zander AR, Schwerdtfeger R, Buchholz S, Kolb HJ, Volin L, Fauser A, Polge E, Schmid C, Mohty M, Rocha V.
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.
Leukemia. 2011 May;25(5):808-13.
32.
Zenz T, Mertens D, Döhner H, Stilgenbauer S.
Importance of genetics in chronic lymphocytic leukemia.
Blood Rev. 2011 May;25(3):131-7.
31.
Schulz AS, Glatting G, Hönig M, Schuetz C, Gatz SA, Grewendorf S, Sparber-Sauer M, Muche R, Blumstein N, Kropshofer G, Suttorp M, Bunjes D, Debatin KM, Reske S, Friedrich W.
Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and non-malignant diseases.
Blood. 2011 Apr 28;117(17):4642-50.
30.
van Gelder M, van Marion A, Goosens V, Bommer M and Leblond V.
Resolution of Waldenström’s macroglubulinemia related absolute neutropenia by immunochemotherapy.
Am J Hematol. 2011 Apr;86(4):380-2.
29.
Bhattacharya N, Diener S, Idler IS, Barth TF, Rauen J, Habermann A, Zenz T, Möller P, Döhner H, Stilgenbauer S, Mertens D.
Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14(+) cells from peripheral blood.
Leukemia. 2011 Apr;25(4):722-6.
28.
Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Kündgen A, Schmidt-Wolf IGH, Götze K, Nachbaur D, Pfreundschuh M, Horst HA, Döhner H, Döhner K.
RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis on 945 Patients from the AML Study Group (AMLSG).
J Clin Oncol. 2011 Apr 1;29(10):1364-72.
27.
Philipp C, Edelmann J, Bühler A, Winkler D, Stilgenbauer S, Küppers R.
Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL.
Int J Cancer. 2011 Apr 1;128(7):1747-50.
26.
Allegra D, Mertens D.
In-vivo quantification of primary microRNA processing by Drosha with a luciferase based system.
25.
Döhner H, Gaidzik VI.
Impact of Genetic Features on Treatment Decisions in AML.
24.
Nattermann J, Vogel M, Nischalke HD, Danta M, Mauss S, Stellbrink HJ, Baumgarten A, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Naumann U, Lutz T, Rausch M, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U.
Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.
23.
Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P, Seiffert M.
Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2.
Haematologica. 2011 Mar;96(3):408-16.
22.
Mohr F, Döhner K, Buske C, Rawat VP.
TET Genes: New players in DNA demethylation and important determinants for stemness.
Exp Hematol. 2011 Mar;39(3):272-81.
21.
Dührsen U, Kratz CP, Flotho C, Lauenstein T, Bommer M, König E, Brittinger G, and Heimpel H.
Long-term outcome of hemizygous and heterozygous carriers of a germline GATA1G208R mutation.
Ann Hematol. 2011 Mar;90(3):301-6.
20.
Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M, Germeroth L, Ringhoffer M, Ringhoffer S, Wiesneth M, Greiner J, Michel D, Mertens D, Rojewski M, Marx M, von Harsdorf S, Döhner H, Seifried E, Bunjes D, Schmitt M.
Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation.
Transfusion. 2011 Mar;51(3):591-599.
19.
Meyer LH, Eckhoff SM, Queudeville M, Kraus JM, Giordan M, Stursberg J, Zangrando A, Vendramini E, Möricke A, Zimmermann M, Schrauder A, Lahr G, Holzmann K, Schrappe M, Basso G, Stahnke K, Kestler HA, Te Kronnie G, Debatin KM.
Early relapse in all is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways.
18.
Cario H, Smith DE, Blom H, Blau N, Bode H, Holzmann K, Pannicke U, Hopfner KP, Rump EM, Ayric Z, Kohne E, Debatin KM, Smulders Y, Schwarz K.
Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease.
Am J Hum Genet. 2011 Feb 11;88(2):226-31.
17.
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG).
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.
Blood. 2011 Feb 10;117(6):1817-21.
16.
Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A, Morgan M, Bomm K, Göhring G, Lübbert M, Kanz L, Fiedler W, Schlegelberger B, Heil G, Schlenk RF, Döhner K, Döhner H, Krauter J, Ganser A, Heuser M.
Prognostic importance of histone methyltransferase Mixed Lineage Leukemia 5 (MLL5) expression in acute myeloid leukemia.
J Clin Oncol. 2011 Feb 20;29(6):682-9.
15.
Bommer M, Nagy A, Schöpflin C, Pauls S, Ringhoffer M, Schmid M.
Cerebrospinal fluid pleocytosis pitfalls and benefit of combined analysis using cytomorphology and flow cytometry.
Cancer Cytopathology. 2011 Feb 25;119(1):20-6.
14.
Marcucci G, Haferlach T, Döhner H.
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications.
J Clin Oncol. 2011 Feb 10;29(5):475-86.
13.
Taskesen E, Bullinger L, Corbacioglu A, Sanders M, Erpelinck C, Wouters BJ, van der Poel-van de Luytgaarde S, Damm F, Krauter J, Ganser A, Schlenk RF, Lowenberg B, Delwel R, Dohner H, Valk PJ, Dohner K.
Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity.
Blood. 2011 Feb 24;117(8):2469-75.
12.
Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF, for the German-Austrian AMLSG.
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2,853 adult patients with newly diagnosed AML.
Blood. 2011 Feb 17;117(7):2137-45.
11.
Mohr J, Helfrich H, Fuge M, Eldering E, Bühler A, Winkler D, Volden M, Kater A, Mertens D, te Raa D, Döhner H, Stilgenbauer S, Zenz T.
DNA damage induced transcriptional programme in CLL: biological and diagnostic implications of functional p53 testing.
Blood. 2011 Feb 3;117(5):1622-32.
10.
Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL, Humphries RK, Karsan A.
MicroRNA-146a disrupts hematopoietic differentiation and survival.
9.
Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J, Kuchenbauer F, Hirst M, Tohyama K, Humphries RK, Lam WL, Marra M, Karsan A.
Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations.
Blood. 2011 Jan 13;117(2):595-607.
8.
Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K.
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
7.
Bender A, Opel D, Naumann I, Kappler R, Friedman L, von Schweinitz D, Debatin KM, Fulda S.
PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
6.
Hofmann S, Babiak A, Greiner J.
Immunotherapy for Myeloproliferative Neoplasms (MPN).
Curr Cancer Drug Targets. 2010 Jan 1;11(1):72-84.
5.
Fiedler K, Sindrilaru A, Terszowski G, Kokai E, Feyerabend TB, Bullinger L, Rodewald HR, Brunner C.
Neutrophil development and function critically depends on Bruton's tyrosine kinase in a mouse model of X-linked agammaglobulinemia.
Blood. 2011 Jan 27;117(4):1329-1339.
4.
Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Bene' MC, Berger U, Buchner T, Burnett A, Cross N, De Witte T, Dohner H, Dombret H, Einsele H, Engelich G, Foa' R, Fonatsch C, Goekbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansman U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Sausele S.
The European LeukemiaNet - Achievements and perspectives.
Haematologica. 2011 Jan;96(1):156-62.
3.
Ellegast* J, Barth* TFE, Schulte M, Bielack SS, Schmid* M, Mayer-Steinacker* R.
Metastasis of Osteosarcoma After 16 Years.
J Clin Oncol. 2011 Jan 20;29(3):e62-6. *Equal contribution
2.
Gale RP, Barosi G, Barbui T, Cervantes F, Döhner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S.
What are RBC-transfusion-dependence and -independence?
Leuk Res. 2011 Jan;35(1):8-11.
1.
Rücker FG*, Bullinger L*, Gribov A, Sill M, Schlenk RF, Lichter P, Döhner H and Döhner K.
Molecular Characterization of AML With ins(21;8)(q22;q22q22) Reveals Similarity to t(8;21) AML.
Genes Chromosomes Cancer. 2011 Jan;50(1):51-8. *Equal contribution
Publikationen 2011
nach oben